Dr. David Rimm
Department of Pathology
Yale University School of Medicine
Brady Memorial Laboratory Room 165
310 Cedar Street - P.O. Box 208023
New Haven, CT 06520-8023

2004

Camp RL, Dolled-Filhart M, Rimm DL.
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.
Clin Cancer Res. 2004 Nov 1;10(21):7252-9.

Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM
Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.
Cancer Res. 2004 Dec 1;64(23):8773-7.

Berger AJ, Camp RL, Divito KA, Kluger HM, Halaban R, Rimm DL
Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome
Cancer Res. 2004 Dec 1;64(23):8767-72.

Giltnane JM, Rimm DL
Technology Insight: identification of biomarkers with tissue microarray technology
Nature Clinical Practice Oncology 1, 104 - 111 (01 Dec 2004) Review

Jaganath, R., Angeletti, C., Levenson, R.M., and Rimm, D.L.
Diagnostic Classification of Urothelial Cells in Urine Cytology Specimens Using Exclusively Spectral Information.
Cancer Cytopathology 2004(in press)

Chelouche Lev, D., Kluger, H.M., Berger, A.J., Rimm, D.L. and Price, J.E.
AlphaB-crystallin as a marker of metastatic potential in breast cancer.
Cancer 2004(in press)

Fadare, O., Mariappan, M.R., Wang, S., Hileeto, D., Mcalpine, J. and Rimm, D.L.
The Histologic Subtype of Ovarian Tumors Affects the Detection Rate by Pelvic Washings
Cancer Cytopathology 2004(in press)

Chung, G.G., Ocal, I.T., Zerkowski, M.P., Dolled-Filhart M , Camp, R.L., and Rimm, D.L.
Beta-catenin and p53 Analyses on a Breast Cancer Tissue Microarray
Cancer 2004(in press)

Kluger, H.M., DeVito, K., Berger, A.M., and Rimm, D.L.
Her2/neu is not a commonly expressed therapeutic target in melanoma a large cohort tissue microarray study.
Melanoma Research 2004(in press)

Angeletti, C., Komitch, V., Halaban, R, and Rimm, D.L.
A Novel Tyramide-Based Tyrosinase Assay for the Detection of Melanoma Cells in Cytological Preparations.
Diag. Cytopathol. 2004(in press)

Rubin, M.A., Zerkowski, M.P., Camp, R.L., Kuefer, R. Hofer, M.D., Chinnaiyan, A.M., and Rimm, D.L.
Quantitative Determination of Expression of the Prostate Cancer Protein Alpha-Methylacyl-CoA Racemase (AMACR) using AQUA: A novel paradigm for automated and continuous biomarker measurements.
Am. J. Pathol. 2004; 164(3): 831-840

Haffty, B. G., Hauser, A., Choi, D. H., Parisot, N., Rimm, D.L., King, B., and Carter, D.
Molecular markers for prognosis after isolated postmastectomy chest wall recurrence.
Cancer 2004; 100: 252-263

Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL.
Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis.
Clin. Cancer Research 2004; 10(1): 173-7.

2003

Harvey, N.R., Levenson, R.M., Rimm, D.L.
Investigation of Automated Feature Extraction Techniques for Applications in Cancer Detection from Multispectral Histopathology Images.
Proc. of SPIE 2003; 5032: 557-566

Berger, A.J., Kluger, H.M., Li, N., Kielhorn, E., Halaban, R., Ronai, Z., and Rimm, D.L.
Subcellular Localization of Activating Transcription Factor 2 (ATF2) in Melanoma Specimens Predicts Patient Survival
Cancer Research 2003; 63:8103-8107

Xie, W., Rimm, D.L., Lin, Y., Shih, W.J. and Reiss, M.
Loss Of Smad Signaling Is Associated With Poor Outcome In Human Colorectal Cancer A Tissue Microarray Analysis.
Cancer J., 2003 Jul-Aug;9(4):302-12.

Provost, E., Yamamoto, Y., Lizardi, I., Stern, J., D'Aquila, T.G., Gaynor, R.B., and Rimm D.L.
Functional correlates of mutations in beta-catenin Exon 3 phosphorylation sites.
J Biol Chem. 2003 Aug 22;278(34):31781-9

Kim, S., Rimm, D.L., Carter, D., Khan, A., Parisot, N., Franco, M. A., Bale, A., and Haffty, B. G
BRCA Status, Molecular Markers, and Clinical Variables in Early, Conservatively Managed Breast Cancer.
Breast J. 2003; 9:167-74.

Camp, R.L., Dolled-Filhart, M., King, B and Rimm, D.L.
Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome.
Cancer Research 2003; 63:1445-1448.

Ocal, I.T., Dolled-Filhart, M.P, D'Aquila, T.G., Camp, R.L. and Rimm, D.L
Tissue Microarray based studies of node-negative breast cancer patients show Met expression associated with worse outcome but not correlated with EGF family receptors.
Cancer 2003; 97(8):1841-1848.

Kang, J.Y., Dolled-Filhart, M.,. Ocal, I.T., Singh, B., Lin, C-Y., Dickson, R.B., Rimm, D.L. and Camp, R.L.
Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator Inhibitor 1 in the Progression of Node-negative Breast Cancer.
Cancer Research 2003; 63:1101-1105.

Dolled-Filhart, M.P., Camp, R.L., Kowalski, D.P., Smith, B.L., and Rimm, D.L.
Tissue Microarray Analysis of Stat3 and Phospho-Stat3 (Tyr705) in Node-Negative Breast Cancer Shows Nuclear Localization is Associated with a Better Prognosis.
Clin Cancer Res. 2003; 9:594-600.

Kielhorn, E., Provost, E., Olsen, D., D'Aquila, T.G., Smith, B.L., Camp, R.L. and Rimm, D.L.
Tissue Microarray-Based Analysis Shows Phospho-beta-catenin Expression in Malignant Melanoma is Associated with Poor Outcome.
Int J Cancer. 2003 Feb 20;103(5):652-6.

King, B.L., Tsai, T..S., Gryga, M., D'Aquila, T.G., Seelig, S.A. Morrison, L., Jacobson, K., Legator, M., Ward, D.C., Rimm, D.L., and Phillips, R.F.
Detection of Chromosomal Instability in Paired Breast Surgery and Ductal Lavage Specimens by Interphase FISH.
Clin Cancer Res 2003; 9 1509-1516

2002

Camp RL, Chung GG, Rimm DL.
Automated subcellular localization and quantification of protein expression in tissue microarrays.
Nat Med. 2002 Nov;8(11):1323-7.

Ernst LM, Rimm DL.
Quantitative examination of mechanophysical tumor cell enrichment in fine-needle aspiration specimens.
Cancer. 2002 Oct 25;96(5):275-9.

Dillon DA, Hipolito E, Zheng K, Rimm DL, Costa JC.
p53 mutations as tumor markers in fine needle aspirates of palpable breast masses.
Acta Cytol. 2002 Sep-Oct;46(5):841-7.

King BL, Crisi GM, Tsai SC, Haffty BG, Phillips RF, Rimm DL.
Immunocytochemical analysis of breast cells obtained by ductal lavage.
Cancer. 2002 Aug 25;96(4):244-9.

Chung GG, Kielhorn EP, Rimm DL.
Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray.
Clin Colorectal Cancer. 2002 Feb;1(4):237-42.

Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M.
Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.
Cancer Res. 2002 Jan 15;62(2):497-505.

Kielhorn E, Schofield K, Rimm DL.
Use of magnetic enrichment for detection of carcinoma cells in fluid specimens.
Cancer. 2002 Jan 1;94(1):205-11.

Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL.
Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis.
Clin Cancer Res. 2001 Dec;7(12):4013-20.

Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E.
Amplification of tissue by construction of tissue microarrays.
Exp Mol Pathol. 2001 Jun;70(3):255-64. Review.

Rimm DL.
Impact of microarray technologies on cytopathology. Overview of technologies and commentary on current and future implications for pathologists and cytopathologists.
Acta Cytol. 2001 Mar-Apr;45(2):111-4. No abstract available.

Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G.
Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis.
Am J Pathol. 2001 Mar;158(3):987-96.

Pradhan D, Lombardo CR, Roe S, Rimm DL, Morrow JS.
α-Catenin binds directly to spectrin and facilitates spectrin-membrane assembly in vivo.
J Biol Chem. 2001 Feb 9;276(6):4175-81.